Physician Views: To what extent and how quickly do US cardiologists anticipate using Amarin's Vascepa?

Late last week, the FDA confirmed that it approved expanded labelling for Amarin's fish-oil-derived drug Vascepa (icosapent ethyl) to include use as an adjunctive therapy to lower the risk of cardiovascular (CV) events in adults with triglyceride levels of 150 mg/dL or more. Patients must also have either established CV disease or diabetes and at least two additional risk factors for CV disease. More here.

Build up to this regulatory decision has been watched closely since positive data from the REDUCE-IT cardiovascular outcomes study were announced last year, with expanded labelling positioning Vascepa as a potential multi-billion dollar product.

In light of the approval, we are snap-polling US cardiologists to gauge how they anticipate using Vascepa in the months and years ahead…

Q. The FDA has approved the use of Vascepa (icosapent ethyl) as an adjunctive (secondary) therapy to reduce the risk of cardiovascular events among adults with elevated triglyceride levels of 150 mg/dL or higher. Patients must also have either established cardiovascular disease or diabetes and two or more additional risk factors for cardiovascular disease. Patients are advised to continue physical activity and maintain a healthy diet.

Do you already prescribe Vascepa to any patients meeting these criteria on an off-label basis?

Never

Rarely

Occasionally

Often

Always

_______

Q. Approval-supporting data from the REDUCE-IT study show that Vascepa reduces the risk of first occurrence of major adverse cardiovascular event by 25% versus placebo in statin-treated adults with persistently elevated triglycerides, and occurrence of all major adverse cardiovascular events (i.e. initial and subsequent events) by 30% versus placebo.

To what percentage of the patients under your care meeting these criteria (i.e. adults with elevated triglyceride levels of 150 mg/dL or higher with either established cardiovascular disease or diabetes and two or more additional risk factors for cardiovascular disease) would you ultimately anticipate prescribing Vascepa to?

____%

_______

Q. How quickly do you anticipate integrating Vascepa into the treatment regimens for the majority of patients you expect to prescribe it to?

Where 1 = very slowly and 5 = very quickly

1            2            3            4            5

_______

Q. Do you anticipate prescribing Vascepa to patients without established cardiovascular disease or diabetes?

Never

Rarely

Occasionally

Often

Always

_______

Q. Do you anticipate prescribing Vascepa as an adjunctive (secondary) therapy to reduce the risk of cardiovascular events among adults with elevated triglyceride levels below 150 mg/dL?

Never

Rarely

Occasionally

Often

Always

_______

Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here.

As always, FirstWord would very much like to receive your feedback and suggestions.

Note: FirstWord Physician Views are a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialties in major markets. To conduct this poll with a different audience, or an entirely different poll, contact us at info@firstwordpharma.com.

Disclaimer: FirstWord follows market research best practices in conducting its Physician Views polls.  However, Physician Views results should be considered directional and clients should use their market research resources for statistical analysis and conclusions required with very high confidence levels.

To read more Physician Views articles, click here.